|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 31/505 | (2006.01) |
| A61K 31/55 | (2006.01) | ||
| A61K 38/17 | (2006.01) | ||
| A61P 35/00 | (2006.01) |
| (11) | Number of the document | 2190429 |
| (13) | Kind of document | T |
| (96) | European patent application number | 08830619.6 |
| Date of filing the European patent application | 2008-09-10 | |
| (97) | Date of publication of the European application | 2010-06-02 |
| (45) | Date of publication and mention of the grant of the patent | 2016-04-20 |
| (46) | Date of publication of the claims translation | 2016-05-25 |
| (86) | Number | PCT/US2008/075903 |
| Date | 2008-09-10 |
| (87) | Number | WO 2009/036099 |
| Date | 2009-03-19 |
| (30) | Number | Date | Country code |
| 971144 P | 2007-09-10 | US | |
| 13372 | 2007-12-13 | US |
| (72) |
LI, Chiang, Jia, US
JIANG, Zhiwei, US
ROGOFF, Harry, US
LI, Youzhi, US
LIU, Jifeng, US
LI, Wei, US
|
| (73) |
Boston Biomedical, Inc.,
640 Memorial Drive, Cambridge, MA 02139,
US
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | STAT3 poveikio inhibitorių ir vėžinių kamieninių ląstelių poveikio inhibitorių naujoji grupė |
| A NOVEL GROUP OF STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL PATHWAY INHIBITORS |
| Payment date | Validity (years) | Amount | |
| 2025-08-28 | 18 | 347.00 EUR |
| 2026-09-10 |